Al­bert Bourla picks a new deal­mak­er to lead the hunt for more drugs to swell Pfiz­er’s pipeline

A new deal­mak­er is join­ing the ex­ec­u­tive crew at Pfiz­er.

The phar­ma gi­ant says that McK­in­sey vet Aamir Ma­lik is jump­ing on board as a new ex­ec­u­tive vice pres­i­dent and “chief busi­ness in­no­va­tion of­fi­cer.” He’s tak­ing the place of John Young, who had ear­li­er an­nounced plans to re­tire from the phar­ma gi­ant af­ter a 34-year run.

Ma­lik has a tough act to fol­low. In his send­off, CEO Al­bert Bourla cred­it­ed Young with es­tab­lish­ing col­lab­o­ra­tions for the phar­ma gi­ant that led to its in­cred­i­bly prof­itable tie-up with BioN­Tech. That al­liance has de­liv­ered a megablock­buster Covid-19 vac­cine that promis­es to earn tens of bil­lions of dol­lars.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER